Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors
In EGFR-treatment naive NSCLC patients, high-level MET amplification is detected in approximately 2–3% and is considered as adverse prognostic factor. Currently, clinical trials with two different inhibitors, capmatinib and tepotinib, are under way both defining different inclusion criteria regardin...
Main Authors: | Carina Heydt, Ann-Kathrin Becher, Svenja Wagener-Ryczek, Markus Ball, Anne M. Schultheis, Simon Schallenberg, Vanessa Rüsseler, Reinhard Büttner, Sabine Merkelbach-Bruse |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037019301801 |
Similar Items
-
Biomarkers for Homologous Recombination Deficiency in Cancer
by: Svenja Wagener-Ryczek, et al.
Published: (2021-06-01) -
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
by: Svenja Wagener-Ryczek, et al.
Published: (2020-05-01) -
MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.
by: Katja Schmitz, et al.
Published: (2015-01-01) -
Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
by: Carina Heydt, et al.
Published: (2020-07-01) -
Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnostics.
by: Carina Heydt, et al.
Published: (2014-01-01)